Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults

Inclusion Criteria:

* Acute lymphoblastic leukemia of the mature B-cell type (L3-ALL)
* High-grade non-Hodgkin's lymphoma of the following subtypes (WHO classification)

  * Burkitt's lymphoma (including atypical Burkitt's lymphoma)
  * Precursor B-lymphoblastic lymphoma
  * Anaplastic large-cell lymphoma (Ki1+, B-, T- oder Null-cell-type)
  * Mediastinal large B-cell-lymphoma (subtype of diffuse large B-cell lymphoma)
* Age = 18 years
* Patient's Informed Consent

Exclusion Criteria:

* Serious complications caused by leukemia/ lymphoma or by a second illness: e.g.

  * Severe, unmanageable complications such as sepsis, pneumonia with oxygen deficiency,
  * Shock, hemorrhage at the time of diagnosis
  * Renal insufficiency from leukemia/lymphoma-unrelated causes
  * Severe cardiac or hepatic insufficiency
  * Severe obstructive or restrictive lung disease that would compromise patient's treatment with intensified chemotherapy
  * HIV infection
  * Secondary lymphoma following prior chemotherapy/ radiotherapy or an active second malignancy
  * Known severe allergy to foreign proteins
* Cytostatic pretreatment for B-ALL/lymphoma (exceptions: short-term administration of steroids = 7 days, single administration of vincristine or cyclophosphamide, one cycle of CHOP, a single administration in an emergency of other cytostatic agents) for another malignant disease within the last 5 years
* Pregnancy/ nursing period
* Severe psychiatric illness or other circumstances giving ground to the assumption that a patient cannot give his consent to therapy or act co-operatively
* Absence of patient's informed consent
* Participation in another clinical study that would possibly interfere with study therapy